COVID-19 (Novel Coronavirus) and Sponsored Research

The University of Dayton Office for Research (OFR) continues to closely follow the COVID-19 outbreak. This page contains information about COVID-19 as it relates to the conduct of research and sponsored projects. This webpage will continue to be updated frequently as new information is received.

Availability of OFR STAFF:

Office of the Vice President for Research: partial remote work.

For meeting requests mailto:danita.nelson@udri.udayton.edu

Contracts and Grants Office (CGO) Proposal Team: Remote work

For inquiries mailto:proposals@udri.udayton.edu

Proposal Development: Remote work

For assistance mailto:amv.adkins@udri.udatvon.edu

Human Subjects Research: Remote work

For assistance mailto:irb@udayton.edu

Technology Partnerships: Remote work.

For assistance mailto:matthew.willenbrink@udri.udayton.edu

Deadlines: Please contact CGO proposal team or review the agencies website for the most current deadline for your submission. Please note that CGO proposal team requires a minimum of 3 days to review and submit proposals. Researchers who fail to follow this timeframe will be disallowed to submit their grants.

Allowability of costs

CGO is reviewing questions relating to the allowability of costs associated with any disruptions to sponsored projects stemming from the coronavirus.

- Send questions to mailto:proposals@udri.udayton.edu
- In order for a cost to be allowable, it will require consistent treatment across all funding sources.
- The federal funding agencies are working on a unified message on these matters. Once it is published, this site will be updated.

Most federal granting agencies allow a grantee approved one year no-cost extension. Please contact CGO for details regarding your award.

Guidance and FAQs from DOD/USAMRAA/CDMRP

Please see this webpage with FAQs for awardees and applicants.

Guidance From NSF on Coronavirus

NSF has established a <u>webpage</u> with guidance specific to their agency with information for awardee organizations, researchers, and reviewers. If you have questions, please feel free to contact your NSF Program Officer or CGO.

Guidance From NIH on Coronavirus and FAOs

NIH has issued the following Notices with guidance for applicants, awardees, and institutions. If you have additional questions, please contact your Sponsored Programs Officer.

Guidance from the Ohio Department of Health and Current Information

NIH

NIH LATE APPLICATION POLICY Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19) (NOT-OD-20-082)

<u>General Frequently Asked Questions (FAQs) - Proposal Submission and Award Management Related to COVID-19</u> (NOT-OD-20-083)

Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19 (NOT-OD-20-086)

Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19 (NOT-OD-20-087)

COVID-19 / coronavirus FOAs (as of 3/23/20)

If you wish to submit to any of these programs, please contact CGO Proposal teamASAP.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)

(NOT-AI-20-030) for NIAID & NIGMS grantees

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

(NOT-HL-20-757) for NHLBI grantees

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047) for NIDA grantees

NIAID news article (2/19/20) on this topic

NIAID's Multi-Pronged Response to the COVID-2019 Outbreak: https://www.niaid.nih.gov/grants-contracts/response-covid-2019-

<u>outbreak?utm_campaign=+41725024&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=</u>

NIAID's 2020 Omnibus Broad Agency Announcement (BAA) is soliciting research on emerging viruses and pandemics under Research Areas 3, 4 and 5. This covers highly pathogenic human coronaviruses: https://grants.nih.gov/grants/quide/notice-files/NOT-AI-20-025.html

This NIAID contract program was announced in 2/10/20 funding alert:

Deadline Program Title Award Type Sponsor Amount

04/09/2020 2020 NIAID Omnibus Broad Agency

<u>Announcement</u>

Details

Contract NIH/NIAID NIAID estimates that the average annual total cost is \$2M per contract, however, the total cost may vary depending upon the scope of the

project

Other existing NIAID programs:

Partnerships for Countermeasures against Select Pathogens (R01) due date 6/29/20 https://grants.nih.gov/grants/quide/rfa-files/RFA-AI-20-028.html

NSF

Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (NSF 20-

052) https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp

The National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, we invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to \$200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to rapid-covid19@nsf.gov.

Other Federal agencies (applied research projects):

Biomedical Advanced Research and Development Authority (BARDA) BAA https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

CDC COVID-19 BAA

 $\frac{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19\&sort=-relevance\&index=\&is active=true\&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19\&sort=-relevance\&index=&is active=true\&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19\&sort=-relevance&index=&is active=true\&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19\&sort=-relevance&index=&is active=true&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19\&sort=-relevance&index=&is active=true&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19\&sort=-relevance&index=&is active=true&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19\&sort=-relevance&index=&is active=true&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19\&sort=-relevance&index=&is active=true&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19\&sort=-relevance&index=&is active=true&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19\&sort=-relevance&index=&is active=true&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=&is active=true&page=2}{\text{https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=&is active=true&page=&is active=true&page=&is active=true&page=&is active=true&page=&is active=&is active=&$

DOD/Dept of Army *potential* RFP for Prototype Development to Combat COVID-19 https://beta.sam.gov/opp/53badf9fb02349e78839a541495efc6a/view